Jazz Pharmaceuticals PLC $JAZZ Shares Newly Bought by JW Asset Management LLC

JW Asset Management LLC purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 11,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,547,000. Jazz Pharmaceuticals makes up about 1.1% of JW Asset Management LLC’s portfolio, making the stock its 14th biggest holding.

Several other large investors have also added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its position in Jazz Pharmaceuticals by 50.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 76,421 shares of the specialty pharmaceutical company’s stock valued at $17,696,000 after buying an additional 25,671 shares during the last quarter. Eurizon Capital SGR S.p.A. lifted its stake in Jazz Pharmaceuticals by 46.1% in the third quarter. Eurizon Capital SGR S.p.A. now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $757,000 after purchasing an additional 1,029 shares during the last quarter. Maryland State Retirement & Pension System raised its stake in shares of Jazz Pharmaceuticals by 19.0% in the third quarter. Maryland State Retirement & Pension System now owns 3,633 shares of the specialty pharmaceutical company’s stock valued at $841,000 after buying an additional 580 shares during the period. Lido Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 5.2% during the 3rd quarter. Lido Advisors LLC now owns 2,644 shares of the specialty pharmaceutical company’s stock valued at $612,000 after buying an additional 131 shares during the last quarter. Finally, Keybank National Association OH lifted its position in shares of Jazz Pharmaceuticals by 0.6% during the 3rd quarter. Keybank National Association OH now owns 10,141 shares of the specialty pharmaceutical company’s stock valued at $2,348,000 after buying an additional 57 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on JAZZ shares. Needham & Company LLC lifted their price objective on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Wells Fargo & Company upped their price objective on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Morgan Stanley increased their target price on shares of Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 3rd. Sanford C. Bernstein reiterated a “market perform” rating and issued a $220.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday. Finally, Barclays boosted their price target on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $294.00.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $240.37 on Friday. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. The business has a 50-day simple moving average of $229.25 and a 200 day simple moving average of $219.25. The stock has a market cap of $15.43 billion, a price-to-earnings ratio of 22.01, a PEG ratio of 0.45 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 52 week low of $136.55 and a 52 week high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.03) by $0.15. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. Jazz Pharmaceuticals’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the previous year, the business posted $8.13 earnings per share. On average, research analysts forecast that Jazz Pharmaceuticals PLC will post 11.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce Cozadd sold 68,808 shares of the firm’s stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $235.95, for a total transaction of $16,235,247.60. Following the sale, the director owned 357,567 shares in the company, valued at $84,367,933.65. This trade represents a 16.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the sale, the executive vice president owned 65,686 shares in the company, valued at $16,401,794.20. The trade was a 53.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 171,342 shares of company stock valued at $41,420,491 over the last quarter. Insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.